Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

BACKGROUND HA-1A is a human monoclonal IgM antibody that binds specifically to the lipid A domain of endotoxin and prevents death in laboratory animals with gram-negative bacteremia and endotoxemia. METHODS To evaluate the efficacy and safety of HA-1A, we conducted a randomized, double-blind trial in patients with sepsis and a presumed diagnosis of gram-negative infection. The patients received either a single 100-mg intravenous dose of HA-1A (in 3.5 g of albumin) or placebo (3.5 g of albumin). Other interventions, including the administration of antibiotics and fluids, were not affected by the study protocol. RESULTS Of 543 patients with sepsis who were treated, 200 (37 percent) had gram-negative bacteremia as proved by blood culture. For the patients with gram-negative bacteremia followed to death or day 28, there were 45 deaths among the 92 recipients of placebo (49 percent) and 32 deaths among the 105 recipients of HA-1A (30 percent; P = 0.014). For the patients with gram-negative bacteremia and shock at entry, there were 27 deaths among the 47 recipients of placebo (57 percent) and 18 deaths among the 54 recipients of HA-1A (33 percent; P = 0.017). Analyses that stratified according to the severity of illness at entry showed improved survival with HA-1A treatment in both severely ill and less severely ill patients. Of the 196 patients with gram-negative bacteremia who were followed to hospital discharge or death, 45 of the 93 given placebo (48 percent) were discharged alive, as compared with 65 of the 103 treated with HA-1A (63 percent; P = 0.038). No benefit of treatment with HA-1A was demonstrated in the 343 patients with sepsis who did not prove to have gram-negative bacteremia. For all 543 patients with sepsis who were treated, the mortality rate was 43 percent among the recipients of placebo and 39 percent among those given HA-1A (P = 0.24). All patients tolerated HA-1A well, and no anti-HA-1A antibodies were detected. CONCLUSIONS HA-1A is safe and effective for the treatment of patients with sepsis and gram-negative bacteremia.

[1]  C. Fisher,et al.  Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. , 1990, Critical care medicine.

[2]  G. Grau,et al.  Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies , 1990, The Journal of experimental medicine.

[3]  J. Ghrayeb,et al.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Clemmer,et al.  Sepsis syndrome: a valid clinical entity , 1989 .

[5]  J F Murray,et al.  An expanded definition of the adult respiratory distress syndrome. , 1988, The American review of respiratory disease.

[6]  J. Schellekens,et al.  Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. , 1988, The Journal of infectious diseases.

[7]  W. R. Mccabe,et al.  Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. , 1988, The Journal of infectious diseases.

[8]  E. Ziegler.  Protective antibody to endotoxin core: the emperor's new clothes? , 1988, The Journal of infectious diseases.

[9]  H. Buller,et al.  ENDOTOXAEMIA: AN EARLY PREDICTOR OF SEPTICAEMIA IN FEBRILE PATIENTS , 1988, The Lancet.

[10]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[11]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[12]  J. McCutchan,et al.  PREVENTION OF GRAM-NEGATIVE SHOCK AND DEATH IN SURGICAL PATIENTS BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPID , 1985, The Lancet.

[13]  H. Kaplan,et al.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T R Fleming,et al.  Designs for group sequential tests. , 1984, Controlled clinical trials.

[15]  U. Zähringer,et al.  Concepts of the chemical structure of lipid A. , 1984, Reviews of infectious diseases.

[16]  J. Fierer,et al.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1982, The New England journal of medicine.

[17]  W. R. Mccabe,et al.  Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients , 1980 .

[18]  W. R. Mccabe,et al.  Limitations of the Usefulness of the Limulus Assay for Endotoxin , 1973 .